Products
Verenafusp Biosimilar Fab Fusion Protein (Insulin Receptor) for Research
Cat No.: GMP-Bios-INN-1455
Anti-INSR/CD220 therapeutic antibody (Pre-made Verenafusp biosimilar,Fab Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Verenafusp (development code GNR-055) is a chimeric Fab fusion protein targeting human insulin receptor (INSR). It is developed by GENERIUM Pharmaceuticals for Mucopolysaccharidosis II in Phase II/III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1455-1mg | 1mg | 3090 |
| GMP-Bios-INN-1455-10mg | 10mg | |
| GMP-Bios-INN-1455-100mg | 100mg | |
| GMP-Bios-INN-1455-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Verenafusp biosimilar, Fab Fusion Protein targeting INSR/CD220: Recombinant therapeutic protein targeting INSR/CD220/Insulin receptor/IR |
| INN Name | Verenafusp |
| Target | INSR/CD220 |
| Format | Fab Fusion Protein |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 5kqv:PQ:CD/4zxb:CD |
| 95-98% SI Structure | 3loh:CD/2dtg:CD/3w14:CD:PQ |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | GENERIUM Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Mucopolysaccharidosis II |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
